2025 年至 2032 年偏頭痛治療市場（依治療劑、給藥途徑及地區分類）

Migraine Therapeutic Market, By Therapeutics, By Route of Administration, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2025年07月31日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

偏頭痛藥物市場規模預計在 2025 年為 68.509 億美元，預計到 2032 年將達到 129.314 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 9.5%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	68.509億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	9.50%	2032年價值預測	129.314億美元

偏頭痛是一種神經系統疾病，其特徵是頭部某一區域出現劇烈的搏動性或搏動性疼痛。疼痛通常為單側搏動性疼痛，且活動時疼痛加劇。偏頭痛是一種容易引起其他徵兆和症狀的頭痛，例如噁心和視力模糊。雖然偏頭痛無法治愈，但藥物可以幫助預防、停止或防止症狀和徵兆惡化。

市場動態

偏頭痛盛行率的上升、對安全有效治療的需求不斷成長、人們對偏頭痛及其治療方法的認知不斷提高以及全球研發的不斷活性化，預計將在預測期內推動全球偏頭痛藥物市場的成長。例如，偏頭痛是一種嚴重且常見的神經系統疾病，嚴重影響生活品質。 2020年，偏頭痛被世界衛生組織列為導致殘障年限損失最多的神經系統疾病。

2022年2月，Biohaven製藥控股有限公司和輝瑞公司報告稱，歐洲藥品管理局（EMA）人用藥品委員會對Rimegepant給予了正面評價。 Rimegepant 75毫克（口溶片）被建議上市許可，用於成人有或無徵兆偏頭痛的急性治療，以及每月發作四次或以上偏頭痛的成人核准性偏頭痛的徵兆治療。

本次調查的主要特點

本報告對全球偏頭痛藥物市場進行了詳細分析，並以 2024 年為基準年，提供了預測期 2025-2032 的市場規模（百萬美元）和年複合成長率(CAGR)。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。
該報告根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，概述了全球偏頭痛治療藥物市場的主要企業。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
全球偏頭痛治療藥物市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球偏頭痛藥物市場的各種策略矩陣來更輕鬆地做出決策。

北美洲
美國
加拿大
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
其他歐洲國家
亞太地區
中國
印度
日本
澳洲
韓國
ASEAN
其他亞太地區
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
南非
北非
中部非洲

第7章競爭態勢

Pfizer Inc.
Novartis International AG
Merck & Co. Inc.
GlaxoSmithKline PLC
Eli Lilly and Company
AstraZeneca PLC
Amgen Inc.
Allergan Inc.
Bausch Health Companies Inc.
Teva Pharmaceutical Industries Ltd.

第 8 章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI575

Migraine Therapeutic Market is estimated to be valued at USD 6,850.9 Mn in 2025 and is expected to reach USD 12,931.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 6,850.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	9.50%	2032 Value Projection:	USD 12,931.4 Mn

Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There's no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.

Market Dynamics

Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2020, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.

In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

Key features of the study

This report provides in-depth analysis of the global migraine therapeutic market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global migraine therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Allergan Inc., Bausch Health Companies Inc., and Teva Pharmaceutical Industries Ltd., among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global migraine therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global migraine therapeutic market.

Market Segmentation

Global Migraine Therapeutic Market, By Therapeutics
- Pain-relieving Medications
- Preventive Medications
Global Migraine Therapeutic Market, By Route of Administration
- Oral and Nasal
- Injection
Global Migraine Therapeutic Market, By Geography
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
- Pfizer Inc.
- Novartis International AG
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- Eli Lilly and Company
- AstraZeneca PLC
- Amgen Inc.
- Allergan Inc.
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapeutics
- Market Snapshot, By Route of Administration
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increase in prevalence of migraine around the world
- Adverse effects of drugs and increasing undiagnosed cases
- Increase in demand for safe and effective treatment
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Migraine Therapeutic Market, By Therapeutics, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pain-relieving Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Preventive Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Migraine Therapeutic Market, By Route of Administration, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral and Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Migraine Therapeutic Market, By Geography, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Country
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Country
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Country
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Country
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Country
South Africa
North Africa
Central Africa

7. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Allergan Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views